Eureka Science proudly announces the collaboration with international societies and organizations for the events; the “6th International Conference on Drug Discovery and Therapy” and the “3rd Biotechnology World Congress” to be held in Dubai, UAE, from February 10th - 12th, 2014 with Dr. Ferid Murad, Nobel Laureate and Prof. Atta-ur-Rahman, FRS as the Co-Presidents of conferences.
Press Releases is unique and effective promotional tool offered from Worldpharmatoday.com aimed at bringing our client’s business message into limelight and more importantly make it reach their target audience. This feature can be utilized to launch new product, promoting existing Pharma product, publish business agreements, annual reports, financial results, corporate performances, important announcements or any important information that has to be conveyed to the target audience.
To add free press releases please click here.
FibroGen Announces Analysis of Peritoneal Dialysis Patients With Chronic Kidney Disease From Roxadustat (FG-4592) Incident Dialysis Study
FibroGen Inc. (FibroGen) today announced the presentation of a Phase 2 subgroup analysis comparing treatment response to roxadustat (FG-4592) a first-in-class oral compound in late stage development in incident peritoneal dialysis (PD) patients and incident hemodialysis (HD) patients for the treatment of anemia in end stage renal disease (ESRD).
Oncodesign and UCB enter into a research collaboration for the early development of new therapeutic agents in neurodegenerative diseases
The partnership is based on Oncodesign's Nanocyclix(R) technology platform for next generation kinase inhibitors and UCB’s expertise in neurology.
Adocia announces the initiation of a clinical trial on its combination of the long-acting insulin Glargine and a fast-acting insulin analog
This phase I/II clinical trial on Type I Diabetics seeks to compare the performance of this Combo based on insulin Glargine with HumalogMix(R).
Avedro Inc. a Boston-based ophthalmic medical device and pharmaceutical company announces today that the first patients have been treated in two new US clinical trials: Lasik with Cross-linking and Pulsed Accelerated Cross-linking.
Advanced research instrumentation pioneer Oxford Optronix launches HypoxyLab™ – the industry’s first benchtop, HEPA-filtered hypoxia workstation
Oxford Optronix, the leading provider of advanced research instrumentation for the clinical medicine and life science industries, today announces the formal launch of HypoxyLab™ – the industry’s first benchtop, HEPA-filtered, precision-controlled hypoxia workstation.
Promethera Biosciences has conducted the trial in Belgium, France, United Kingdom, Italy and Israel, treating twenty patients affected by very rare liver-based metabolic diseases.
Neuroptis Biotech, the ophthalmology drug research and development specialist, announces positive results in preclinical trials of the eye-drop formulation of its ML7 product. ML7 is intended for use in the treatment of eye surface diseases, particularly dry eye.
Covance Inc. , one of the world's largest and most comprehensive drug development companies, and PathoQuest, a pioneer in the field of pathogen detection, today announce an exclusive agreement to collaborate in providing Next-Generation Sequencing (NGS) based biosafety assessments.
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, has completed its efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA).
Page 1 of 57